Sign up today for our free Psoriasis Health Tips, delivered four times per year by email.

In each issue, you will get:

  • the latest developments in psoriasis treatment options;
  • seasonal strategies for minimizing the challenges posed by psoriasis and psoriatic arthritis;
  • information on clinical trials that are currently recruiting psoriasis patients;
  • easy to read summaries of the most important scientific papers concerning psoriatic disease;
  • and answers to your questions.

You don’t want to miss any of the important news that could help you manage – and ultimately defeat – your psoriasis or psoriatic arthritis. Of course, if you ever decide you’re no longer interested in receiving it, just click the unsubscribe link at the bottom of every issue.

The nonprofit Psoriasis Cure Now educates psoriasis patients and the general public about psoriasis, and works for increased research on psoriatic disease and to ensure that patients can access the cutting-edge psoriasis and psoriatic arthritis therapies that are transforming lives.

If you have ideas, questions, or concerns, let us know.

The Latest Psoriasis News

Experimental psoriatic arthritis treatment filgotinib shows strong response in clinical trials
Experimental psoriatic arthritis treatment filgotinib shows strong response in clinical trials

Gilead Sciences and Galapagos jointly announced results from Phase Two (mid-stage) clinical trials for their JAK1 inhibitor filgotinib for psoriatic arthritis. The companies are jointly developing the investigational treatment. JAK inhibitors, taken as pills, are receiving much attention for their ability to help people with rheumatoid arthritis (RA), psoriatic arthritis, Continue Reading…

Taltz challenges Humira in head to head clinical trial treating psoriatic arthritis
Taltz challenges Humira in head to head clinical trial treating psoriatic arthritis

Eli Lilly and Company shared new data from its 52-week, head-to-head biologic clinical trial pitting its Taltz (ixekizumab) against AbbVie’s longtime blockbuster Humira (adalimumab) in patients with psoriatic arthritis who had not yet tried a biologic. Here’s the bottom line for those of you who just want the answers without Continue Reading…

Tremfya approval in U.S. for psoriatic arthritis looks likely
Tremfya approval in U.S. for psoriatic arthritis looks likely

Tremfya (guselkumab), is approved by the U.S. Food and Drug Administration (FDA) and regulators elsewhere for the treatment of adults with moderate to severe plaque psoriasis. It is an IL-23 inhibitor that is very successful at improving skin psoriasis. It was approved in Europe in 2019 for active psoriatic arthritis, Continue Reading…